iTeos Therapeutics, Inc Earning Date (ITOS)

USA |NASDAQ |USD

ITOS Earnings Date

|
Report Date Period Ending EPS Forecast Last Quarter's EPS Last Year's EPS
Aug 10, 2022 Jun 2022 - - $-0.75
Report Date Period Ending Revenue Forecast Last Quarter’s Revenue Last Year’s Revenue
Aug 10, 2022 Jun 2022 - - $0.00

Iteos Therapeutics, Inc's next earnings date is Wednesday, Aug 10, 2022 for the fiscal quarter ending Jun 2022.

ITOS Earnings Date & History Chart

ITOS Earnings & Revenue Forecast

ITOS Earnings Forecast

|
Period End # of Analysts EPS Forecast Low EPS Forecast High EPS Forecast
Period End # of Analysts EPS Forecast Low EPS Forecast High EPS Forecast
Dec 2022 5 $1.90 $-4.96 $5.07

ITOS Earnings Revision Trend

|
Period End Up/Down 1M 1M Trend 2M Trend 3M Trend
Period End Up/Down 1M 1M Trend 2M Trend 3M Trend
Dec 2022 4 / 0 $-3.12 $-3.12 $-2.63

ITOS Revenue Forecast

|
Period End # of Analysts Revenue Forecast Low Revenue Forecast High Revenue Forecast
Period End # of Analysts EPS Forecast Low EPS Forecast High EPS Forecast
Dec 2022 5 $246.08M $0.00 $417.91M

ITOS Earnings Date & Revenue History

ITOS Earnings History

|
Show More
Show More

ITOS Revenue History

|
Show More
Show More

Iteos Therapeutics, Inc Next Earnings Date & Report

ITOS Next Earnings Date & Report Preview: Jun 2022 (FQ)

ITOS's next earnings date is Wednesday, Aug 10, 2022 for the fiscal quarter ending Jun 30, 2022.

Iteos Therapeutics, Inc Previous Earnings Dates & Reports

ITOS Previous Earnings Date & Report Recap: Mar 2022 (FQ)

Iteos Therapeutics, Inc's previous earnings date was May 11, 2022 for its fiscal quarter ended Mar 31, 2022.

ITOS Previous Earnings Date & Report Recap: Dec 2020 (FY)

Iteos Therapeutics, Inc's previous annual earnings date was Mar 24, 2021 for its fiscal year ended Dec 31, 2020.

ITOS's earnings per share (EPS) was $-1.20.

Revenues were $0.00.

The company reported a net income of $-38.03M.

Iteos Therapeutics, Inc reported a free cash flow of $-25.53M for its fiscal year, compared to $-23.87M a year ago.